Erin D. Michos, MD, MHS, FAHA interviews investigator Rafael Díaz, MD about the results of PREPARE-IT 2, which he presented during #AHA21.
Evaluated the use of icosapent ethyl in non-hospitalized rates and mortality, among covid positive patients. the focus and we say, okay, shall we prevent complications were included in the study, and there are two or three by a kind of, not telemedicine, but similar to telemedicine, about 2,000 people were randomized, more were enrolled, in terms of pcr, because that was
One of the inclusion so, positive pcr, was the most important inclusion criteria. we found that, indication for hospitalization, or death, with confidence intervals, that went beyond the unit. i think there was only 50 in each arm about icosapent ethyl, so, this was a clinical trial, without any lab parameter. we didn’t see in those individuals a difference seen in,
We don’t know in this population because we haven’t got they showed a very clear reduction in the c-reactive protein i mean, you’ve used a really high dose of icosapent ethyl of cardiovascular events, and yet, of course it was only and we have settle bleeding in both groups and settle atrial i agree everything trended in the favorable direction and thank you for your time
Here today in the studio. (soft upbeat music plays)
Transcribed from video
PREPARE-IT 2 Results By AHAScienceNews
